Ipertrofan (Mepartricin)

Mepartricin, the active ingredient in Ipertrofan, is a macrolide antibiotic presented as an oral formulation for oral use. It is employed primarily to manage chronic prostatitis and related pelvic disorders in adult males. GNH USA supplies Ipertrofan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mepartricin is used in conditions affecting the prostate and pelvic region, where its antibacterial and anti‑inflammatory actions are beneficial.

Chronic prostatitis: reduces bacterial load and inflammation within the prostate gland. Chronic pelvic pain syndrome: alleviates pain and improves urinary symptoms. Adjunct in benign prostatic hyperplasia: may improve lower urinary tract symptoms when used alongside standard therapy.

Mepartricin may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Nausea: occasional upset stomach after dosing. - Diarrhea: loose stools that resolve with continued therapy. - Headache: mild to moderate intensity. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate medical attention. - Hepatic enzyme elevation: significant increase in liver function tests. - Neutropenia: marked reduction in white blood cell count. - Stevens‑Johnson syndrome: rare severe skin reaction. - Severe skin rash: extensive erythema or blistering. - Eosinophilia: elevated eosinophil count indicating hypersensitivity.

Before initiating Mepartricin therapy, consider the following safety measures. - Pregnancy: avoid unless potential benefit justifies the risk. - Breastfeeding: not recommended due to unknown excretion in milk. - Renal impairment: assess kidney function and adjust if necessary. - Hepatic dysfunction: monitor liver enzymes regularly. - Drug interactions: review all concomitant medications for possible conflicts. - Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Mepartricin can interact with several drug classes; careful review is essential.

Major Interactions (Avoid): - Macrolide antibiotics (e.g., erythromycin): additive risk of QT prolongation. - Anticoagulants (e.g., warfarin): increased bleeding tendency. - Strong CYP450 inhibitors (e.g., ketoconazole): may raise Mepartricin plasma levels.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes for imbalances. - Immunosuppressants (e.g., cyclosporine): watch for enhanced toxicity.